Human Insulin Market Size, Share, and Growth Forecast for 2024 - 2031

Human Insulin Market by Type (Modern, Traditional), Type of Diabetes (Type 1, Type 2), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Regional Analysis from 2024 to 2031

ID: PMRREP3308

January 2025

187 Pages

Author : Abhijeet Surwase

Healthcare

Preview Segmentation

North America Leads with Rising Prevalence of Type 1 Diabetes

North America is emerging as a dominating force in the human insulin market and is anticipated to hold a share of 41.4% in 2024. It is projected to witness a CAGR of 8.4% through 2031. This growth is driven by the strong presence of leading insulin manufacturers, intense competition, and rising prevalence of type 1 diabetes.

According to the American Diabetes Association (ADA), around 2.0 million people in the U.S., including 304,000 children and adolescents, live with type 1 diabetes.

The significant rise in insulin prices over the past decade has further bolstered North America's share of the global market, making it a key contributor to industry revenue. For example,

In 2023, The Centers for Disease Control and Prevention (CDC) reported that the U.S. spent nearly US$ 413 Bn annually in medical expenses related to diabetes care.

Substantial increase in insulin prices in the U.S. over the past decade has significantly contributed to revenue generation. Despite growing advocacy for price controls, the market remains lucrative, driven by ongoing investments in research and development.

Novel insulin delivery systems, such as insulin pens and pumps, are also gaining popularity, enhancing treatment adherence and quality of life for diabetes patients. North America’s robust healthcare infrastructure and favorable insurance reimbursement policies further support market expansion. These factors collectively enable the region to command a prominent share of the global human insulin industry, making it a key driver of industry growth.

Get Your CustomizationGet Your Customization

Modern Human Insulin Dominates Amid Surging Diabetes Prevalence

Modern human insulin dominates the market, and it held around 80% of the share in 2024. It will likely witness a CAGR of 5.1% through 2031. This is attributed to the fact that extensive research is being conducted to bring out this type of human insulin in the market.

The way of administration for both traditional and modern human insulin is through drugs or delivery devices. Among the drugs, there are insulin analogues and biosimilars (NovoRapid/Novolog, Lantus, and Humalog) and human insulin biologics (Mixtard, Insulatard, and Actrapid, Humulin, and Insuman). The delivery devices include pens, pen needles, and syringes.

The number of diabetic patients across the globe is rising at an alarming rate. This, in turn, calls for a greater quantity of human insulin to be brought to the market. Hence, traditional human insulin is there to stay. However, to address the rising demands, modern human insulin is something both healthcare practitioners and end-customers are looking up to.

Human Insulin Market Introduction and Trend Analysis

The global human insulin market is experiencing steady growth, driven by rising diabetes prevalence and developments in insulin formulations. Insulin, a critical therapy for managing diabetes, continues to evolve with the development of biosimilars, offering cost-effective alternatives to traditional insulin products.

Such innovations are particularly beneficial in emerging markets, where affordability and access remain significant challenges. Digital health solutions also play a key role, with technologies such as mobile apps and Continuous Glucose Monitors (CGMs) enabling more personalized and effective diabetes management.

Strategic partnerships and local production initiatives like the collaboration between Novo Nordisk and Aspen Pharmacare are addressing regional insulin shortages and improving market access. As a result, the market is likely to see further expansion, particularly in regions with high unmet needs and surging diabetes rates. These trends indicate a positive outlook for the human insulin industry in the forecast period.

human insulin market insights and key trends

Request Free sampleRequest Free sample

Historical Growth and Course Ahead

From 2019 to 2023, the global human insulin market witnessed steady growth. It was mainly driven by increasing diabetes prevalence, technological developments in insulin delivery, and rising investments in biosimilars.

The market was valued at around US$ 16.1 Bn in 2019, reaching about US$ 18.8 Bn by 2023, with a CAGR of nearly 4.5% from 2019 to 2023. This growth was attributed to rising incidence of diabetes worldwide, improved access to insulin therapies, and high demand for novel insulin delivery devices such as pens and pumps.

From 2024 to 2031, the market is anticipated to maintain a robust growth trajectory. With a growing focus on biosimilars, cost-effective insulin options, and continued innovations in long-acting and rapid-acting insulin formulations, the market is projected to witness a CAGR of 5.1% through 2031.

Rising diabetes cases, particularly in emerging markets, coupled with innovations in personalized treatment and digital health solutions for diabetes management, will continue to drive demand. Government initiatives to improve access to insulin, along with technological integration in treatment plans, will likely shape the market in the next ten years.

Market Growth Drivers

Rising Prevalence of Diabetes to Bolster Growth Worldwide

Increasing global prevalence of diabetes is a primary driver for the human insulin market. For example,

According to the International Diabetes Federation (IDF), nearly 537 million adults aged 20 to 79 had diabetes in 2021, a figure projected to reach 783 million by 2045. This alarming growth highlights the high demand for effective diabetes management solutions, including human insulin products.

Type 1 diabetes, in particular, requires regular insulin administration for survival, further boosting the market. Additionally, technological developments in insulin delivery systems, such as pens, pumps, and smart insulin devices, are improving treatment outcomes and patient compliance. Companies are investing heavily in research to develop innovative, longer-acting insulin formulations and biosimilars to meet this growing demand.

Lifestyle changes and rising obesity rates are significant risk factors for type 2 diabetes, which are increasing the patient population. With healthcare systems worldwide emphasizing better diabetes management and governments implementing supportive reimbursement policies, the human insulin industry is poised for robust growth in the next ten years.

Demand for Over-the-counter (OTC) Insulin to Skyrocket in Future

Regulatory changes in certain regions have paved the way for OTC insulin products, increasing accessibility for patients who previously faced barriers to obtaining prescriptions. For instance,

Walmart partnered with Novo Nordisk to launch ReliOn NovoLog, an affordable analog insulin available over the counter. The product is sold at a significantly reduced price compared to prescription insulin, making it accessible for uninsured or underinsured individuals. It includes options for vials and FlexPen delivery devices, offering flexibility for different patient needs.

Market Restraining Factors

Pricing Disparities and Regulatory Challenges May Hamper Demand

The human insulin industry faces several significant restraints that could hinder its growth. One of the primary challenges is the uneven pricing of insulin across different regions. In developed countries like the U.S., insulin prices have increased substantially over the past decade, creating affordability issues for several patients and putting pressure on the healthcare system.

The price disparity is even more evident in emerging economies, where access to insulin remains limited due to high costs and inadequate healthcare infrastructure. For instance, the World Health Organization (WHO) has highlighted that access to affordable insulin is a leading issue in low- and middle-income countries. It is resulting in millions of people being under-treated or untreated for diabetes.

Stringent regulations for drug approvals, especially in emerging markets, contribute to delays in introducing new insulin formulations. The lengthy approval process can lead to a demand-supply imbalance, where demand for insulin exceeds the supply, further exacerbating access issues.

Regulatory bottlenecks delay the entry of biosimilars and new treatments, which could help lower costs and improve access. These factors combined are likely to restrain the market, limiting the potential for global growth. It is especially evident in regions where insulin access is critical for managing the rising diabetes prevalence.

Key Market Opportunities

Innovations in Digital Health, Biosimilars, and Strategic Alliances Create Prospects

The global human insulin industry is poised for steady growth, with several future opportunities available for key players. A key opportunity lies in the development and rise of biosimilars, which are set to address affordability challenges, particularly in emerging markets.

Regulatory barriers are loosening, and approval processes are becoming more streamlined. Hence, biosimilars are gaining traction and offering cost-effective alternatives to traditional insulin products. Companies that invest in biosimilars, such as insulin glargine and other long-acting insulin formulations, can tap into markets where access to affordable insulin is critical. These include low- and middle-income countries.

Developments in digital health and smart insulin delivery devices present significant opportunities. Integrating insulin management with digital technologies such as mobile apps and Continuous Glucose Monitors (CGMs) can enhance patient outcomes and adherence to treatment plans. Demand for such solutions is on the rise as diabetes management becomes increasingly personalized and tech driven.

Rising Cases of Pediatric Diabetes to Open the Door to New Opportunities

Insulin suppliers have a chance to reach the underprivileged group as the number of instances of pediatric diabetes rises. To address this demand, specialized insulin formulations for kids and family support initiatives are being created. Businesses can greatly increase their market share by concentrating on pediatric formulations, such as rapid-acting insulins for younger populations. For example,

As of 2021, around 652,000 children worldwide are living with type 1 diabetes. There were an estimated 41,600 new cases of type 2 diabetes among children and adolescents globally in the same year.
In the U.S., the prevalence among youth increased from 0.34 per 1,000 in 2001 to 0.67 per 1,000 in 2017, indicating a rising trend.
India has one of the most prominent numbers of children with type 1 diabetes. The prevalence among children is estimated at 111,500 cases.

Competitive Landscape for the Human Insulin Market

Novo Nordisk A/S dominates the human insulin industry and is likely to maintain its leadership due to its strategic partnerships and innovations in drug discovery technologies. Additionally, substantial investments in research to develop unique treatment solutions have solidified the company’s strong market position.

The global human insulin industry features intense competition, with key players like Novo Nordisk A/S, Sanofi, Eli Lilly and Company, and Biocon leading the industry. These companies leverage strategies such as partnerships, biosimilar developments, and regional expansions to strengthen their market positions.

Recent initiatives, including Novo Nordisk’s partnership with Aspen Pharmacare for insulin production in South Africa and Biocon’s acquisition of Viatris’ biosimilar business, highlight the dynamic nature of the market. Furthermore, significant investments in research and innovations in insulin delivery systems, such as pens and pumps, are intensifying competition.

Recent Industry Developments

In August 2024, BF Biosciences Limited (BFBL), headquartered in Pakistan, introduced ‘Ferulin’ a human insulin. In its efforts to prevent diabetes, diversify its product line, and increase the accessibility of life-saving medications, the launch represents a critical turning point.
In September 2023, Denmark-based Novo Nordisk partnered with Aspen Pharmacare Holdings Limited and Aspen SA Operations (Pty) Ltd to establish human insulin production in South Africa, further strengthening local manufacturing capabilities.

Companies Covered in Human Insulin Market

Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Biocon
Tonghua Dongbao Pharmaceutical Co., Ltd.
Adocia
Merck and Co., Inc.
Pfizer, Inc.
Wockhardt
Julphar
Bristol-Myers Squibb Company
GlaxoSmithKline Plc.
Oramed Pharmaceuticals, Inc.
Others

Frequently Asked Questions

The market is estimated to increase from US$ 19.8 Bn in 2024 to US$ 26.9 Bn by 2031.

The global human insulin industry is being propelled by rising diabetes prevalence.

Novo Nordisk A/S, Eli Lilly and Company, Sanofi, and Biocon are few of the leading industry players.

The industry is projected to record a CAGR of 5.1% during the forecast period from 2024 to 2031.

A prominent opportunity lies in rising biosimilar insulin production, which is driven by surging diabetes prevalence and affordability demands in emerging countries.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

1. Executive Summary
   1.1. Global Human Insulin Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overviews
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Challenges
       2.2.5. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Global Sectorial Outlook
       2.3.2. Global GDP Growth Outlook
       2.3.3. Global Healthcare Spending Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   3.1. Drug Adoption Analysis
   3.2. Value Chain Analysis
       3.2.1. List of End-user/Marketplaces
           3.2.1.1. Retail
           3.2.1.2. E-Commerce
       3.2.2. List of End User (Industry)
   3.3. Key Deals and Mergers
   3.4. PESTLE Analysis
   3.5. Porter’s Five Force Analysis
4. Global Human Insulin Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   4.1. Key Highlights
       4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
       4.1.2. Absolute $ Opportunity
   4.2. Market Size (US$ Bn) Analysis and Forecast
       4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
       4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
   4.3. Global Human Insulin Market Outlook: Type
       4.3.1. Introduction / Key Findings
       4.3.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019 - 2023
       4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
           4.3.3.1. Modern Human Insulin
               4.3.3.1.1. Fast-acting
               4.3.3.1.2. Long-acting
               4.3.3.1.3. Premix
           4.3.3.2. Traditional Human Insulin
               4.3.3.2.1. Long-acting
               4.3.3.2.2. Short-acting
               4.3.3.2.3. Fast-acting
               4.3.3.2.4. Premix
       4.3.4. Market Attractiveness Analysis: Type
   4.4. Global Human Insulin Market Outlook: Type of Diabetes
       4.4.1. Introduction / Key Findings
       4.4.2. Historical Market Size (US$ Bn) Analysis, By Type of Diabetes, 2019 - 2023
       4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type of Diabetes, 2024 - 2031
           4.4.3.1. Diabetes Type 1
           4.4.3.2. Diabetes Type 2
       4.4.4. Market Attractiveness Analysis: Type of Diabetes
   4.5. Global Human Insulin Market Outlook: Distribution Channel
       4.5.1. Introduction / Key Findings
       4.5.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019 - 2023
       4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
           4.5.3.1. Retail Pharmacies
           4.5.3.2. Hospital Pharmacies
           4.5.3.3. Online Pharmacies
       4.5.4. Market Attractiveness Analysis: Distribution Channel
5. Global Human Insulin Market Outlook: Region
   5.1. Key Highlights
   5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
   5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024 - 2031
       5.3.1. North America
       5.3.2. Europe
       5.3.3. East Asia
       5.3.4. South Asia and Oceania
       5.3.5. Latin America
       5.3.6. Middle East & Africa
   5.4. Market Attractiveness Analysis: Region
6. North America Human Insulin Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   6.1. Key Highlights
   6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
       6.2.1. By Country
       6.2.2. By Type
       6.2.3. By Type of Diabetes
       6.2.4. By Distribution Channel
   6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
       6.3.1. U.S.
       6.3.2. Canada
   6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
       6.4.1. Modern Human Insulin
           6.4.1.1. Fast-acting
           6.4.1.2. Long-acting
           6.4.1.3. Premix
       6.4.2. Traditional Human Insulin
           6.4.2.1. Long-acting
           6.4.2.2. Short-acting
           6.4.2.3. Fast-acting
           6.4.2.4. Premix
   6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type of Diabetes, 2024 - 2031
       6.5.1. Diabetes Type 1
       6.5.2. Diabetes Type 2
   6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
       6.6.1. Retail Pharmacies
       6.6.2. Hospital Pharmacies
       6.6.3. Online Pharmacies
   6.7. Market Attractiveness Analysis
7. Europe Human Insulin Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   7.1. Key Highlights
   7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
       7.2.1. By Country
       7.2.2. By Type
       7.2.3. By Type of Diabetes
       7.2.4. By Distribution Channel
   7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
       7.3.1. Germany
       7.3.2. France
       7.3.3. U.K.
       7.3.4. Italy
       7.3.5. Spain
       7.3.6. Russia
       7.3.7. Türkiye
       7.3.8. Rest of Europe
   7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
       7.4.1. Modern Human Insulin
           7.4.1.1. Fast-acting
           7.4.1.2. Long-acting
           7.4.1.3. Premix
       7.4.2. Traditional Human Insulin
           7.4.2.1. Long-acting
           7.4.2.2. Short-acting
           7.4.2.3. Fast-acting
           7.4.2.4. Premix
   7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type of Diabetes, 2024 - 2031
       7.5.1. Diabetes Type 1
       7.5.2. Diabetes Type 2
   7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
       7.6.1. Retail Pharmacies
       7.6.2. Hospital Pharmacies
       7.6.3. Online Pharmacies
   7.7. Market Attractiveness Analysis
8. East Asia Human Insulin Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   8.1. Key Highlights
   8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
       8.2.1. By Country
       8.2.2. By Type
       8.2.3. By Type of Diabetes
       8.2.4. By Distribution Channel
   8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
       8.3.1. China
       8.3.2. Japan
       8.3.3. South Korea
   8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
       8.4.1. Modern Human Insulin
           8.4.1.1. Fast-acting
           8.4.1.2. Long-acting
           8.4.1.3. Premix
       8.4.2. Traditional Human Insulin
           8.4.2.1. Long-acting
           8.4.2.2. Short-acting
           8.4.2.3. Fast-acting
           8.4.2.4. Premix
   8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type of Diabetes, 2024 - 2031
       8.5.1. Diabetes Type 1
       8.5.2. Diabetes Type 2
   8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
       8.6.1. Retail Pharmacies
       8.6.2. Hospital Pharmacies
       8.6.3. Online Pharmacies
   8.7. Market Attractiveness Analysis
9. South Asia and Oceania Human Insulin Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   9.1. Key Highlights
   9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
       9.2.1. By Country
       9.2.2. By Type
       9.2.3. By Type of Diabetes
       9.2.4. By Distribution Channel
   9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
       9.3.1. India
       9.3.2. Southeast Asia
       9.3.3. ANZ
       9.3.4. Rest of South Asia & Oceania
   9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
       9.4.1. Modern Human Insulin
           9.4.1.1. Fast-acting
           9.4.1.2. Long-acting
           9.4.1.3. Premix
       9.4.2. Traditional Human Insulin
           9.4.2.1. Long-acting
           9.4.2.2. Short-acting
           9.4.2.3. Fast-acting
           9.4.2.4. Premix
   9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type of Diabetes, 2024 - 2031
       9.5.1. Diabetes Type 1
       9.5.2. Diabetes Type 2
   9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
       9.6.1. Retail Pharmacies
       9.6.2. Hospital Pharmacies
       9.6.3. Online Pharmacies
   9.7. Market Attractiveness Analysis
10. Latin America Human Insulin Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   10.1. Key Highlights
   10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
       10.2.1. By Country
       10.2.2. By Type
       10.2.3. By Type of Diabetes
       10.2.4. By Distribution Channel
   10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
       10.3.1. Brazil
       10.3.2. Mexico
       10.3.3. Rest of Latin America
   10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
       10.4.1. Modern Human Insulin
           10.4.1.1. Fast-acting
           10.4.1.2. Long-acting
           10.4.1.3. Premix
       10.4.2. Traditional Human Insulin
           10.4.2.1. Long-acting
           10.4.2.2. Short-acting
           10.4.2.3. Fast-acting
           10.4.2.4. Premix
   10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type of Diabetes, 2024 - 2031
       10.5.1. Diabetes Type 1
       10.5.2. Diabetes Type 2
   10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
       10.6.1. Retail Pharmacies
       10.6.2. Hospital Pharmacies
       10.6.3. Online Pharmacies
   10.7. Market Attractiveness Analysis
11. Middle East & Africa Human Insulin Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   11.1. Key Highlights
   11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
       11.2.1. By Country
       11.2.2. By Type
       11.2.3. By Type of Diabetes
       11.2.4. By Distribution Channel
   11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
       11.3.1. GCC Countries
       11.3.2. Egypt
       11.3.3. South Africa
       11.3.4. Northern Africa
       11.3.5. Rest of Middle East & Africa
   11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
       11.4.1. Modern Human Insulin
           11.4.1.1. Fast-acting
           11.4.1.2. Long-acting
           11.4.1.3. Premix
       11.4.2. Traditional Human Insulin
           11.4.2.1. Long-acting
           11.4.2.2. Short-acting
           11.4.2.3. Fast-acting
           11.4.2.4. Premix
   11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type of Diabetes, 2024 - 2031
       11.5.1. Diabetes Type 1
       11.5.2. Diabetes Type 2
   11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
       11.6.1. Retail Pharmacies
       11.6.2. Hospital Pharmacies
       11.6.3. Online Pharmacies
   11.7. Market Attractiveness Analysis
12. Competition Landscape
   12.1. Market Share Analysis, 2023
   12.2. Market Structure
       12.2.1. Competition Intensity Mapping By Market
       12.2.2. Competition Dashboard
   12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       12.3.1. Novo Nordisk A/S.
           12.3.1.1. Overview
           12.3.1.2. Segments and Products
           12.3.1.3. Key Financials
           12.3.1.4. Market Developments
           12.3.1.5. Market Strategy
       12.3.2. Eli Lilly and Company.
       12.3.3. Sanofi.
       12.3.4. Biocon.
       12.3.5. Tonghua Dongbao Pharmaceutical Co., Ltd.
       12.3.6. Adocia
       12.3.7. Merck & Co., Inc.
       12.3.8. Pfizer, Inc.
       12.3.9. Wockhardt.
       12.3.10. Julphar
       12.3.11. Bristol-Myers Squibb Company.
       12.3.12. GlaxoSmithKline Plc.
       12.3.13. Oramed Pharmaceuticals, Inc.
13. Appendix
   13.1. Research Methodology
   13.2. Research Assumptions
   13.3. Acronyms and Abbreviations

Market Attributes	Key Insights
Human Insulin Market Size (2024E)	US$ 19.8 Bn
Projected Market Value (2031F)	US$ 26.9 Bn
Global Market Growth Rate (CAGR 2024 to 2031)	5.1%
Historical Market Growth Rate (CAGR 2019 to 2023)	4.5%

Attributes	Details
Forecast Period	2024 to 2031
Historical Data Available for	2019 to 2023
Market Analysis	US$ Billion for Value
Key Country Covered	North America Europe East Asia South Asia and Oceania Latin America Middle East and Africa
Key Market Segments Covered	Type Type of Diabetes Distribution Channel Regions
Key Companies Profiled	Novo Nordisk A/S Eli Lilly and Company Sanofi Biocon Tonghua Dongbao Pharmaceutical Co., Ltd. Adocia Merck and Co., Inc. Pfizer, Inc. Wockhardt Julphar Bristol-Myers Squibb Company GlaxoSmithKline Plc. Oramed Pharmaceuticals, Inc. Others
Report Coverage	Market Forecast Company Share Analysis Competition Intelligence DROT Analysis Market Dynamics and Challenges Strategic Growth Initiatives
Customization and Pricing	Available upon request

Market Attributes	Key Insights
Human Insulin Market Size (2024E)	US$ 19.8 Bn
Projected Market Value (2031F)	US$ 26.9 Bn
Global Market Growth Rate (CAGR 2024 to 2031)	5.1%
Historical Market Growth Rate (CAGR 2019 to 2023)	4.5%

Attributes	Details
Forecast Period	2024 to 2031
Historical Data Available for	2019 to 2023
Market Analysis	US$ Billion for Value
Key Country Covered	North America Europe East Asia South Asia and Oceania Latin America Middle East and Africa
Key Market Segments Covered	Type Type of Diabetes Distribution Channel Regions
Key Companies Profiled	Novo Nordisk A/S Eli Lilly and Company Sanofi Biocon Tonghua Dongbao Pharmaceutical Co., Ltd. Adocia Merck and Co., Inc. Pfizer, Inc. Wockhardt Julphar Bristol-Myers Squibb Company GlaxoSmithKline Plc. Oramed Pharmaceuticals, Inc. Others
Report Coverage	Market Forecast Company Share Analysis Competition Intelligence DROT Analysis Market Dynamics and Challenges Strategic Growth Initiatives
Customization and Pricing	Available upon request

Human Insulin Market Size, Share, and Growth Forecast for 2024 - 2031

Human Insulin Market by Type (Modern, Traditional), Type of Diabetes (Type 1, Type 2), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Regional Analysis from 2024 to 2031

Human Insulin Market Size and Share Analysis

North America Leads with Rising Prevalence of Type 1 Diabetes

Modern Human Insulin Dominates Amid Surging Diabetes Prevalence